Aclarion Provides 2025 Update and 2026 Corporate Outlook
Aclarion, Inc. (ACON)
Company Research
Source: GlobeNewswire
Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growthCompany aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain today provided a comprehensive corporate update, including financial results and strategic progress as the Company enters 2026 advancing its proprietary Nociscan platform. Market Adoption & Growth
Show less
Read more
Impact Snapshot
Event Time:
ACON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACON alerts
High impacting Aclarion, Inc. news events
Weekly update
A roundup of the hottest topics
ACON
News
- Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028GlobeNewswire
- Aclarion Provides 2025 Update and 2026 Corporate Outlook [Yahoo! Finance]Yahoo! Finance
- Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial DataGlobeNewswire
- Aclarion (NASDAQ:ACON) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACON&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> tMarketBeat
- Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)GlobeNewswire
ACON
Analyst Actions
- 11/20/25 - Ascendiant Capital
ACON
Sec Filings
- 1/13/26 - Form 8-K
- 1/9/26 - Form 8-K
- 1/9/26 - Form 424B5
- ACON's page on the SEC website